Fig. 4

MiR-496 targets to CTNNB1 in prostate cancer. a Venn diagram exhibited 16 qualified messenger RNAs (mRNAs) collected by using starbase. b The expression of 16 mRNAs in normal prostate epithelial cell (RWPE1) and PCa cells (DU145 and LNCaP) was detected by RT-qPCR. c The conjectured binding sites between miR-496 and CTNNB1 were showed. d RIP assay detected the enrichment of LINC00689, miR-496 and CTNNB1 in Anti-IgG or Anti-Ago of DU145 and LNCaP cells. e Luciferase reporter assay examined the luciferase activity of CTNNB1 3′UTR-WT/Mut in transfected DU145 and LNCaP cells (NC mimics, miR-496 mimics and miR-496 mimics + pcDNA3.1/LINC00689). f, g RNA or protein level of CTNNB1 or β-catenin was measured respectively by RT-qPCR and western blotting in miR-496 inhibitor and sh-LINC00689#1 transfected DU145 and LNCaP cells (48 h for plasmid transfection). GAPDH was an internal control. Error bars represent the mean ± SD of at least three independent experiments. ^**P < 0.01